Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection

RATIONALE: Arikace is a liposomal amikacin preparation for aerosol delivery with potent Pseudomonas aeruginosa killing and prolonged lung deposition. OBJECTIVES: To examine the safety and efficacy of 28 days of once-daily Arikace in cystic fibrosis (CF) patients chronically infected with P aeruginos...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Clancy, J P, Dupont, L, Konstan, M W, Billings, J, Fustik, S, Goss, C H, Lymp, J, Minic, P, Quittner, A L, Rubenstein, R C, Young, K R, Saiman, L, Burns, J L, Govan, J R W, Ramsey, B, Gupta, R
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2013
Teme:
Cystic Fibrosis
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3756431/
https://ncbi.nlm.nih.gov/pubmed/23749840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2012-202230
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki